Polarity marked X-rhodamine–labeled MTs were polymerized as described (26, 27, 69) and stabilized with 20 μM paclitaxel. MT•motor complexes were performed with a final concentration of 0.5 μM tubulin (paclitaxel-stabilized α,β-tubulin) and 2.5 μM kinesin dimer. Perfusion chambers were constructed using acid-washed coverslips and incubated first with 40 μg/mL Penta-His antibodies (Qiagen) for 10 min followed by a 5-min incubation of blocking buffer (PME80; 1.5 mM magnesium acetate, 500 μg/mL casein, 25 mM glucose, 0.2 mg/mL glucose oxidase, 175 μg/mL catalase, 0.3 mg/mL creatine phosphokinase, 2 mM phosphocreatine, 0.5% β-mercaptoethanol, 15 μM paclitaxel). MT•motor complexes were then introduced into the chamber and allowed to bind for 5 min. Unbound complexes were removed with excess blocking buffer. Gliding via the surface-bound motors was activated by introducing Activity Buffer (blocking buffer supplemented with 1 mM MgATP and either 3% DMSO or 5 μM propofol at 3% DMSO). MT gliding was imaged by TIRF microscopy at 564 nm using a 180-ms exposure time and a 10- (K560) or 20-s (KIF3) interval for 20 min at 25 °C. The velocity of gliding MTs (Fig. 1) was determined by tracking the leading edge of the moving polarity-marked MTs using the tracking algorithm on AxioVision 4.8.2 software (Carl Zeiss Microscopy, Inc.). MTs were scored that moved at least eight frames (≥80 s for K560 and ≥160 s for KIF3AC and KIFAB) and met the following criteria: MTs were entirely in the field of view, were ≥3 but ≤8 μm in length, and traveled in a clearly defined path. MT gliding velocity data were then compiled, and a Gaussian fit of the histogram provided the mean velocity ±SEM. Persistence of MT gliding was defined as the percentage of scorable MTs that remained attached to the surface-bound kinesins and continued to glide. The data reported in Fig. 1 G–I represent a minimum of 3 different experimental days, with six to eight movies collected per day. Within each field of observation, ∼10–60 MTs were scored for persistence of gliding.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.